Inventiva S.A. (EPA:IVA)

France flag France · Delayed Price · Currency is EUR
3.650
+0.010 (0.27%)
Oct 16, 2025, 12:40 PM CET
0.27%
Market Cap506.51M
Revenue (ttm)16.97M
Net Income (ttm)-311.07M
Shares Out139.15M
EPS (ttm)-3.53
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume364,450
Average Volume483,628
Open3.695
Previous Close3.640
Day's Range3.555 - 3.830
52-Week Range2.000 - 5.550
Beta0.75
RSI36.92
Earnings DateSep 26, 2025

About Inventiva

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-β, a pre-clinical program for th... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 118
Stock Exchange Euronext Paris
Ticker Symbol IVA
Full Company Profile

Financial Performance

In 2024, Inventiva's revenue was 14.09 million, a decrease of -38.24% compared to the previous year's 22.82 million. Losses were -184.21 million, 66.8% more than in 2023.

Financial Statements

News

Inventiva Announces the Implementation of a New ATM Program

Daix (France), New York City (New York, United States), October 14, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focuse...

1 day ago - GlobeNewsWire

Inventiva (IVA) Gets Boosted Price Target from HC Wainwright & Co. | IVA Stock News

Inventiva (IVA) Gets Boosted Price Target from HC Wainwright & Co. | IVA Stock News

6 days ago - GuruFocus

Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025

Daix (France), New York City (New York, United States), October 7, 2025 -  Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused...

8 days ago - GlobeNewsWire

Inventiva Names Andrew Obenshain CEO

(RTTNews) - Inventiva S.A. (IVA), a clinical-stage biopharmaceutical company, announced on Wednesday that it has appointed Andrew Obenshain as Chief Executive Officer.

15 days ago - Nasdaq

Inventiva Appoints Andrew Obenshain as Chief Executive Officer

Daix (France), New York City (New York, United States), October 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused ...

15 days ago - GlobeNewsWire

Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday.

16 days ago - Benzinga

Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1...

16 days ago - Benzinga

Earnings Scheduled For September 29, 2025

Companies Reporting Before The Bell • Inventiva (NASDAQ: IVA) is projected to report quarterly loss at $0.41 per share on revenue of $5.31 million. • Uxin (NASDAQ: UXIN) is estimated to report earni...

17 days ago - Benzinga

Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update

Daix (France), New York City (New York, United States), September 29, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focus...

17 days ago - GlobeNewsWire

Top Wall Street Forecasters Revamp Inventiva Expectations Ahead Of H1 Earnings

Inventiva S.A. (NASDAQ: IVA) will release earnings results for the first half of the year, after the closing bell on Monday, Sept.

17 days ago - Benzinga

Top Wall Street Forecasters Revamp Inventiva Expectations Ahead Of H1 Earnings

Inventiva S.A. (NASDAQ: IVA) will release earnings results for the first half of the year, after the closing bell on Monday, Sept. 29 . Analysts expect the Daix, France-based company to report H1 los...

17 days ago - Benzinga

Preview: Inventiva's Earnings

Inventiva (NASDAQ: IVA) is gearing up to announce its quarterly earnings on Monday, 2025-09-29. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

19 days ago - Benzinga

Here's Why Inventiva (IVA) Is a Great 'Buy the Bottom' Stock Now

Inventiva (IVA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall ...

19 days ago - Nasdaq

Costco Wholesale, Concentrix And 3 Stocks To Watch Heading Into Friday

With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows: Heritage Financial Corp (NASDAQ: HFWA) announced plans to acquire O...

20 days ago - Benzinga

Insights into Inventiva's Upcoming Earnings

Inventiva (NASDAQ: IVA) is set to give its latest quarterly earnings report on Friday, 2025-09-26. Here's what investors need to know before the announcement. Analysts estimate that Inventiva will re...

20 days ago - Benzinga

Inventiva to Host Analyst and Investor Event on October 8, 2025

Daix (France), New York City (New York, United States), September 24, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focus...

21 days ago - GlobeNewsWire

Inventiva (IVA) Positioned as Prime Acquisition Target

Inventiva (IVA) Positioned as Prime Acquisition Target

27 days ago - GuruFocus

Inventiva to Participate in Upcoming September Investor Conferences

Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focuse...

5 weeks ago - GlobeNewsWire

Today's Analyst Rating: Inventiva (IVA) Receives 'Buy' Rating from HC Wainwright & Co. ...

Today's Analyst Rating: Inventiva (IVA) Receives 'Buy' Rating from HC Wainwright & Co. | IVA Stock News

6 weeks ago - GuruFocus

Alibaba To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Guggenhei...

6 weeks ago - Benzinga

Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Daix (France), New York City (New York, United States), August 11, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused ...

2 months ago - GlobeNewsWire

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the ...

2 months ago - GlobeNewsWire